ABSTRACT
A major goal of genomic medicine is to quantify the disease risk of genetic variants. Here, we report the penetrance of 37,772 clinically relevant variants (including those reported in ClinVar1 and of loss-of-function consequence) for 197 diseases in an analysis of exome sequence data for 72,434 individuals over five ancestries and six decades of ages from two large-scale population-based biobanks (BioMe Biobank and UK Biobank). With a high-quality set of 5,359 clinically impactful variants, we evaluate disease prevalence in carriers and non-carriers to interrogate major determinants and implications of penetrance. First, we associate biomarker levels with penetrance of variants in known disease-predisposition genes and illustrate their clear biological link to disease. We then systematically uncover large numbers of ClinVar pathogenic variants that confer low risk of disease, even among those reviewed by experts, while delineating stark differences in variant penetrance by molecular consequence. Furthermore, we ascertain numerous variants present in non-European ancestries and reveal how increasing carrier age modifies penetrance estimates. Lastly, we examine substantial heterogeneity of penetrance among variants in known disease-predisposition genes for conditions such as familial hypercholesterolemia and breast cancer. These data indicate that existing categorical systems for variant classification do not adequately capture disease risk and warrant consideration of a more quantitative system based on population-based penetrance to evaluate clinical impact.
Competing Interest Statement
RD received grants from AstraZeneca, grants and nonfinancial support from Goldfinch Bio, is a scientific co-founder, consultant and equity holder for Pensieve Health, and is a consultant for Variant Bio.
Funding Statement
IF is supported by T32GM007280 the Medical Scientist Training Program Training Grant from the National Institute of General Medical Sciences of the National Institutes of Health. RD is supported by R35GM124836 from the National Institute of General Medical Sciences of the National Institutes of Health, and R01HL139865 from the National Heart, Lung, and Blood Institute of the National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board of the Icahn School of Medicine at Mount Sinai approved this study, which uses de-identified data.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Added supplementary material
Data Availability
The UKB data may be browsed at http://biobank.ndph.ox.ac.uk/showcase/ and access to data can be requested at https://www.ukbiobank.ac.uk/register-apply/. More information about BioMe can be found at https://icahn.mssm.edu/research/ipm/programs/biome-biobank/researcher-faqs. The complete penetrance dataset used for all analyses is provided (Supplementary Tables 9 and 10) with no restrictions on the data released.
